Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
1.58 p
0.33 p(18.56%)
At close: 4:00 PM EDT
1.58 p
0.33 p(18.56%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume25.52K
Average Volume (3M)280.29K
Market Cap
£4.91M
Enterprise Value22.37 p
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume450,730
30 Day Avg. Volume280,293
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract-service ModelThe contract-service model gives Proteome Sciences a direct route to monetize its analytical capabilities without relying solely on internally funded drug programs. Serving pharmaceutical, biotechnology and academic customers also places the business in research markets where outsourced proteomics can support recurring project demand.
Specialized Proteomics CapabilitiesThe company’s specialized mass spectrometry workflows address technically demanding protein analysis needs across biomedical research and drug development. This capability can support customer value through experimental design, analytical execution and bioinformatics outputs rather than commoditized laboratory services alone.
Improving Cash PerformanceCash generation remained negative, but the substantial reduction in free-cash-flow consumption compared with 2024 indicates improved near-term cash discipline or operating performance. If sustained, this trend could reduce funding pressure and improve the company’s ability to support operations from internally generated cash.
Bears Say
Revenue And Profitability DeclineThe deterioration in revenue and gross profit shows that current activity is not absorbing the company’s cost base effectively. Large operating and net losses reduce internal funding capacity, weaken earnings visibility and make sustained investment in proteomics capabilities more financially difficult.
Stressed Balance SheetRising debt combined with deeply negative equity indicates limited balance-sheet flexibility and a capital structure under strain. This can constrain investment choices, increase dependence on refinancing or new capital, and leave the company more exposed if operating losses persist over the coming periods.
Negative And Volatile Cash FlowEven after improving from the prior year, negative free cash flow means the business is not yet self-funding its operations and investment needs. Historical volatility further reduces confidence in predictable cash generation, potentially requiring external financing while the company remains loss-making.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £4.91M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Apr 01, 2027 which is in 206 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went up 4.396%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.